Haemonetics (NYSE:HAE) Releases FY 2024 Earnings Guidance

Haemonetics (NYSE:HAEGet Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.900-4.000 for the period, compared to the consensus earnings per share estimate of 3.890. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

Haemonetics Stock Up 0.0 %

HAE opened at $77.13 on Thursday. Haemonetics has a twelve month low of $74.13 and a twelve month high of $95.26. The company has a quick ratio of 2.19, a current ratio of 3.28 and a debt-to-equity ratio of 0.84. The company has a 50-day moving average price of $83.45 and a 200 day moving average price of $86.70. The company has a market cap of $3.91 billion, a PE ratio of 30.98, a price-to-earnings-growth ratio of 1.98 and a beta of 0.34.

Analysts Set New Price Targets

HAE has been the subject of several research analyst reports. StockNews.com downgraded shares of Haemonetics from a strong-buy rating to a buy rating in a research report on Tuesday, January 16th. Barrington Research cut their price objective on shares of Haemonetics from $114.00 to $105.00 and set an outperform rating for the company in a report on Friday, November 3rd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $103.40.

Read Our Latest Stock Report on Haemonetics

Institutional Trading of Haemonetics

Institutional investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. increased its holdings in Haemonetics by 65.2% in the 4th quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 135 shares during the last quarter. State of Wyoming acquired a new stake in Haemonetics in the 4th quarter valued at approximately $28,000. Belpointe Asset Management LLC grew its stake in shares of Haemonetics by 65.5% in the first quarter. Belpointe Asset Management LLC now owns 455 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 180 shares in the last quarter. Quarry LP grew its stake in shares of Haemonetics by 262.7% in the second quarter. Quarry LP now owns 584 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 423 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its stake in shares of Haemonetics by 21.7% in the second quarter. Parkside Financial Bank & Trust now owns 786 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 140 shares in the last quarter. Institutional investors and hedge funds own 99.38% of the company’s stock.

About Haemonetics

(Get Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.

Further Reading

Earnings History and Estimates for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.